A. Todd

464 total citations · 1 hit paper
8 papers, 343 citations indexed

About

A. Todd is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Genetics. According to data from OpenAlex, A. Todd has authored 8 papers receiving a total of 343 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 1 paper in Genetics. Recurrent topics in A. Todd's work include Lung Cancer Treatments and Mutations (8 papers), HER2/EGFR in Cancer Research (6 papers) and Colorectal Cancer Treatments and Studies (5 papers). A. Todd is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), HER2/EGFR in Cancer Research (6 papers) and Colorectal Cancer Treatments and Studies (5 papers). A. Todd collaborates with scholars based in Japan, South Korea and United Kingdom. A. Todd's co-authors include Yuri Rukazenkov, Jhanelle E. Gray, Riyaz Shah, Fumio Imamura, Margarita Majem, Aleksandra Markovets, Juliann Chmielecki, Byoung Chul Cho, J. Carl Barrett and Yi Cheng and has published in prestigious journals such as Annals of Oncology, Clinical Pharmacology & Therapeutics and Journal of Thoracic Oncology.

In The Last Decade

A. Todd

8 papers receiving 337 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study

2018 269 citations Suresh S. Ramalingam, Yi Cheng et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. Todd Japan	5	323	252	124	84	30	8	343
Y. Ohe Japan	4	289 0.9×	240 1.0×	122 1.0×	77 0.9×	35 1.2×	12	326
M.R. García Campelo Spain	9	301 0.9×	284 1.1×	119 1.0×	90 1.1×	32 1.1×	35	387
J.C.-H. Yang Taiwan	5	281 0.9×	263 1.0×	94 0.8×	46 0.5×	22 0.7×	12	353
Craig Stephens United States	11	242 0.7×	211 0.8×	144 1.2×	107 1.3×	28 0.9×	20	382
Masayuki Yasugi Japan	9	241 0.7×	240 1.0×	132 1.1×	48 0.6×	38 1.3×	22	358
Corinne Clifford United States	10	214 0.7×	202 0.8×	91 0.7×	113 1.3×	43 1.4×	14	348
B.C. Cho South Korea	8	232 0.7×	204 0.8×	90 0.7×	47 0.6×	19 0.6×	33	280
Janice J.N. Li Canada	9	219 0.7×	178 0.7×	114 0.9×	132 1.6×	30 1.0×	16	335
Hideko Isozaki Japan	9	198 0.6×	207 0.8×	209 1.7×	54 0.6×	43 1.4×	31	374

Countries citing papers authored by A. Todd

Since Specialization

Citations

This map shows the geographic impact of A. Todd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Todd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Todd more than expected).

Fields of papers citing papers by A. Todd

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Todd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Todd. The network helps show where A. Todd may publish in the future.

Co-authorship network of co-authors of A. Todd

This figure shows the co-authorship network connecting the top 25 collaborators of A. Todd. A scholar is included among the top collaborators of A. Todd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Todd. A. Todd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Yang, Jincheng, Aarti Sawant‐Basak, A. Todd, et al.. (2025). Population Pharmacokinetics and Exposure‐Response Analysis of First‐Line Osimertinib Plus Chemotherapy in Patients with EGFR ‐Mutated Advanced NSCLC. Clinical Pharmacology & Therapeutics. 118(5). 1110–1121. 1 indexed citations

2.

Valdiviezo, Natalia, Isamu Okamoto, Brett Hughes, et al.. (2024). 4O First-line (1L) osimertinib (osi) ± platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: FLAURA2 post-progression outcomes. ESMO Open. 9. 102583–102583. 13 indexed citations

3.

Jänne, Pasi A., David Planchard, Paul Howarth, A. Todd, & Kunihiko Kobayashi. (2019). OA07.01 Osimertinib Plus Platinum/Pemetrexed in Newly-Diagnosed Advanced EGFRm-Positive NSCLC; The Phase 3 FLAURA2 Study. Journal of Thoracic Oncology. 14(10). S222–S223. 13 indexed citations

4.

Gray, Jhanelle E., Nir Peled, Aleksandra Markovets, et al.. (2019). Longitudinal circulating tumour DNA (ctDNA) monitoring for early detection of disease progression and resistance in advanced NSCLC in FLAURA. Annals of Oncology. 30. v921–v922. 4 indexed citations

5.

Planchard, David, Michael Boyer, Arunee Dechaphunkul, et al.. (2018). Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes. Annals of Oncology. 29. ix150–ix150. 2 indexed citations

6.

Planchard, David, Michael Boyer, Jin Sun Lee, et al.. (2018). 128O Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes. Journal of Thoracic Oncology. 13(4). S72–S73. 13 indexed citations

7.

Ramalingam, Suresh S., Yi Cheng, C. Zhou, et al.. (2018). Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study. Annals of Oncology. 29. viii740–viii740. 269 indexed citations breakdown →

8.

Cho, Byoung Chul, Changdong Zhou, Fumio Imamura, et al.. (2018). Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study. Annals of Oncology. 29. ix177–ix177. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact